MD+DI: COVID-19 One Year Later: Can’t Keep a Medical Device Startup Down

How one medtech startup and its preclinical research partner overcame pandemic-related obstacles to continue its medical device research project. Prior to COVID-19, VentureMed was on a roll. The Minneapolis, MN-based company’s first-generation Flex Vessel Prep System had demonstrated promising clinical performance following FDA clearance and the company was preparing to introduce an improved second-generation device. […]

Cardiovascular News: FLEX Vessel Prep™ System Data Presented During Leipzig Interventional Course (LINC) 2021

Trio of studies demonstrate that FLEX Vessel Prep System safely and effectively modifies obstructive plaque to facilitate delivery of definitive therapies MINNEAPOLIS, Jan. 27, 2021 — VentureMed Group, Inc. (VentureMed), a privately-held medical device innovator, announced today that data from three studies evaluating the use of its FLEX Vessel Prep (VP) System were presented during […]

Medical Alley: COVID-19 and Quarantine – Can’t keep a medical device start-up down

COVID-19 has significantly and adversely affected preclinical research and clinical trials across the universe of life science companies as a result of the suspension of elective procedures in the U.S. and globally, as well as the challenges posed by travel bans, the furlough of or requirement that clinical study personnel work remotely, restrictions on access […]

Endovascular Today: Computational Model Suggests a New Paradigm for Accelerated Treatment Optimization With Paclitaxel Devices

August 28, 2019—CBSET announced that its scientists have published data and analyses that provide critical insights into the interplay between target anatomy and device attributes in determining balloon- and stent-based paclitaxel retention in healthy and diseased arteries. According to CBSET, these findings may transform the understanding of the safety and efficacy of paclitaxel-coated devices used […]

Endovascular Today: Lesion Preparation Using Diamondback 360 OAS Shown to Enhance Paclitaxel Distribution in Calcified PAD

September 11, 2017—CBSET announced that its scientists have published data and analyses regarding the barrier effects of calcified plaque on drug delivery and the treatment success of adjunctive lesion preparation therapy in the treatment of peripheral atherosclerosis. CBSET is a not-for-profit preclinical research institute dedicated to translational research, education, and advancement of medical technologies. According […]

Endovascular Today: Preclinical Study Evaluates Primary Lesion Treatment With CSI’s Orbital Atherectomy System Before Drug Delivery in Calcified PAD

May 20, 2015—CBSET, a preclinical biomedical research institute, announced findings from a cadaver study suggesting that modification of atherosclerotic plaque with the Diamondback 360 orbital atherectomy system (Cardiovascular Systems, Inc. [CSI]) improved drug uptake in calcified peripheral lesions. Gunnar Tepe, MD, from RoMed Hospital in Rosenheim, Germany, stated in CBSET’s announcement, “This preclinical study could have a significant […]